Cision PR Newswire

Final OS Analysis Results from Phase III OptiTROP-Lung04 Study of Sacituzumab Tirumotecan (sac-TMT) Presented at 2026 ESMO

Median OS was extended by 8.5 months compared with platinum-based doublet chemotherapy (25.9 vs 17.4 months), with a 31% reduction in the risk...

AI & Genomics Advances Bring New Hope to Lung Cancer Burden in Asia

SINGAPORE, Feb. 5, 2025 /PRNewswire/ -- Asia is the region most impacted by lung cancer, accounting for 63.1% of newly diagnosed lung cancers and...

Aussie sleeptech firm unveils breakthrough test

MELBOURNE, Australia, Feb. 5, 2025 /PRNewswire/ -- Australian medical technology company Optalert has revealed a breakthrough test for sleep issues, expanding access to sleep health...

Polyplastics to Launch 40% Glass-filled Recycled DURAFIDE (R) PPS Based on New Post-industrial Recycling System

TOKYO, Feb. 5, 2025 /PRNewswire/ -- Polyplastics Co., Ltd., a global leader in engineering plastics, has announced plans to launch a 40% glass-reinforced grade...

China Medical University and Healthcare System Pioneers AI-Driven Drug Discovery and Allogeneic CAR-T Therapy: A Groundbreaking Leap in Cancer Treatment

TAICHUNG, Feb. 5, 2025 /PRNewswire/ -- Healthcare Expo Taiwan is a professional-oriented exposition involving healthcare, information/communication, technology, biopharmaceutical and medical device industries. Attended by...